“Dependant on the info We now have observed during the TRIDENT-1 demo, repotrectinib has the possible to become a fresh common of care selection for sufferers with domestically Sophisticated or metastatic ROS1 fusion-beneficial lung most cancers.” Make sure you be aware that because o